Supernus Pharmaceuticals, Inc. (SUPN) Net Income by Year
Supernus Pharmaceuticals, Inc. reported a net loss of $38.6M in fiscal year 2025. This represents a decrease of 152.2% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to a $109.9M net loss. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Supernus Pharmaceuticals, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
SUPN Net Income by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | TTM | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$109.9M | -$38.6M-152.2% | $73.9M+5584.6% | $1.3M-97.9% | $60.7M+13.7% | $53.4M-57.9% | $127.0M+12.3% | $113.1M+1.9% | $111.0M+93.8% | $57.3M-37.2% | $91.2M+554.2% | $13.9M+227.6% | -$10.9M+88.2% | -$92.3M-99.4% | -$46.3M-186.0% | $53.8M |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
SUPN Net Income by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What net income means
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.
More Supernus Pharmaceuticals, Inc. financials
Frequently Asked Questions
What was Supernus Pharmaceuticals, Inc.'s net income in fiscal year 2025?
Supernus Pharmaceuticals, Inc. reported a net loss of $38.6M in fiscal year 2025.
How fast is Supernus Pharmaceuticals, Inc.'s net income growing?
Supernus Pharmaceuticals, Inc. (SUPN) net income fell by 152.2% year over year, from $73.9M to -$38.6M in fiscal year 2025.
What is Supernus Pharmaceuticals, Inc.'s net income over the last twelve months?
Supernus Pharmaceuticals, Inc. (SUPN) reported a $109.9M net loss over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
How has Supernus Pharmaceuticals, Inc.'s net income changed over the years?
Across the 15 fiscal years this page covers, Supernus Pharmaceuticals, Inc. (SUPN) net income went from $53.8M in fiscal year 2011 to -$38.6M in fiscal year 2025.
What was Supernus Pharmaceuticals, Inc.'s net income in the most recent quarter?
Supernus Pharmaceuticals, Inc. (SUPN) reported -$58.4M in net income in Q2 2026. This represents a decrease of 359.4% from the same quarter a year earlier.
What does net income mean on a financial statement?
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Supernus Pharmaceuticals, Inc. (SUPN) reported on that line in every period on record.